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the tuberculosis (tB) disease is still widely found even though BCg vaccine given to many people. 
Ineffectiveness of the BCG vaccine is one of causes that make the difficulties in preventing TB transmission. 
objective of the research was to determine the immunogenicity of katg protein of M. tuberculosis clinical iso-
late L19 in mice. the katg protein as antigen was prepared by expression of the katg gene of M. tuberculosis 
clinical isolate L19 in Escherichia coli BL21 using pColdII-DNA vector. After purification by affinity chro-
matography, the katg was vaccinated to mice to detect its immunogenicity. the expression of katg in e. coli 
BL21 could result in katg protein with molecular weight 80 kda in sodium dodecyl sulfate gel electrophoresis 
(SDS-PAGE). The pure KatG protein could significantly stimulate the immune response of mice by trigger-
ing the antibodies production of Igg1, Igg2a, Igg2b, Igg2c, Igg3, and IgM. the highest antibody level was 
obtained when the mice were vaccinated by KatG L19 with the dose of 45 μg/ml. Of the antibodies, the IgG2c 
isotype was dominantly produced in the blood serum. the katg protein exhibited a high immunogenici ty in 
mice, so it is possible to develop as a vaccine candidate for tB. a clinical test should be performed in a future 
to ensure its safety as a therapeutic protein.
k e y w o r d s : katg,  immunogenicity, M. tuberculosis, vaccine, clinical isolate.
T uberculosis (TB) is a major health problem throughout the world causing a large number of deaths, more than any other single infec-
tious disease, that is caused by Mycobacterium tu-
berculosis infection. There were strategies to reduce 
the spread of TB including the use of Anti TB thera-
peutic, but the pandemics of Multidrug-Resistant TB 
(MDR TB) have emerged since 1990 that causing 
TB more difficult to treat [1]. Tuberculosis control 
with preventive actions through the development of 
a vaccine became one of the main concerns in cur-
rent TB control program. Bacillus Calmette Guerin 
(BCG) is a TB vaccine that contains live bacteria 
that have been weakened (attenuated), it can stimu-
late the immune system but do not cause disease in 
healthy people. The BCG vaccine can not be given 
to people who are clinically immunosuppressed [2]. 
The BCG is currently used in many countries with 
a high prevalence of TB to prevent childhood tu-
berculous meningitis and miliary disease [3]. It is 
also approved by the FDA for vaccination against 
tuberculosis and for the treatment of bladder cancer 
[4]. In spite of the BCG vaccine is used throughout 
the world, the facts showed BCG is still not effective 
because the TB cases are still high. The protection 
provided by BCG varies widely from 0-80%, then it 
continuously decrease up to 17% in the next 15 years 
[1]. In an effort to answer those problems, is neces-
sary to develop a new TB vaccine.
© 2018 Purkan P. et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
63
DNA vaccine encoding the type of protein 
natu rally EAST - 6 and KatG has been tested on 
mice and it reported to increase the immune re-
sponse in the mouse cells producing antibodies, then 
they were classified as intracellular pathogenic pro-
teins.  Although DNA vaccine may provide an im-
mune response that is quite good, the use of a DNA 
vaccine becomes ineffective if the DNA cannot be 
expressed into proteins in the host cell. Therapeutic 
proteins and peptides have the potential to elicit im-
mune responses resulting in anti-drug antibodies [5].
The katg gene from M. tuberculosis clinical 
isolate L19 has been cloned in in escherichia coli 
using – DNA vector [6]. The gene that encodes an 
intracelular protein with molecular weight 80 kDa 
has been reported as one of pathogenic intracelular 
protein [6-9]. The KatG is also classified by Tuber-
cuList as a virulence factor that participates in the 
response to stress and host oxidative reactions. The 
KatG protein also represents a catalase-peroxidase of 
Rv1908c which is grouped as one of the surface-ex-
posed proteins that is involved in cell wall biogene-
sis and maintenance [10, 11]. The surface-exposed 
proteins are excellent targets for the host adaptive 
immune system, so they are potentially used for the 
develop ment of vaccines for mycobacterial disease 
[10]. The katg gene expression is needed to provide 
its protein, then further used to search its potential 
as TB vaccine. 
The effectiveness of a vaccine depends upon 
the level of specificity of protein antigens to induce 
the immune system to produce specific antibodies, 
so it is necessary to create a pure protein to be used 
as a vaccine. Immunogenicity of protein vaccine 
candidate should be investigated in the target popu-
lation since animal testing and in vitro models can-
not predict immune response in humans. In addition, 
immunogenicity has a role in demonstrating product 
comparability following manufacturing changes and 
similarity in the context of biosimilar development 
[11]. Currently, detection of a product’s immuno-
genicity involves measuring antibodies specifically 
generated against the vaccine candidate. The vac-
cine is said to be ideal if the concentration is low 
enough effective to induce high antibody production 
and be able to induce the formation of a specific type 
of anti body which has a half-length. 
Immunogenicity of KatG L19 protein from 
Mycobacterium tuberculosis has been unknown. 
Based on the case, it was made the purification of 
crude extract of KatG protein from Mycobacterium 
tuberculosis local clinical isolate and followed by the 
immunogenicity assay in mice. The immunogenici-
ty test was conducted to determine the presence (or 
absence) of antibodies based on the ability of the an-
tibodies to recognize the KatG protein in mice. Ad-
ditionally, it was also prepared to detect antibodies 
with desired specificities such as IgM, IgG subclas-
ses etc [5].
materials and methods
samples. The escherichia coli BL21 (DE3) 
carrying of pCold II-katg L19 recombinant was ob-
tained from the laboratory of Biochemistry, Faculty 
of Sciences and Technology, Airlangga University, 
used to produce the KatG protein. Female mice Mus 
musculus strain Balb/C, 8-10 weeks old, weighing 
25-30 gr, were obtained from the PUSVETMA Sura-
baya.
expression of Katg protein. The recombinant 
of e. coli [pCold II-katg L19] was cultured in Lu-
ria Bertani (LB) medium composed of 0,5% (w/v) 
yeast extract, 1% (w/v) tryptone, 1% (w/v) NaCl and 
100 μg/ml of ampicillin, shaking it at 150 rpm and 
at a temperature of 37 °C until obtained the optical 
density of cells 0.5-0.6 at λ 600 nm [6-8]. The cul-
ture was then moved to incubator at 15 °C for 30 min 
without shaking, added with 0.1 mM IPTG and re-
incubated at 15 °C with shaking speed at 150 rpm for 
24 hours. The cells were separated by centrifugation 
at 5.000 g at 4 °C for 10 min, and washed with lysis 
buffer (50 mM Tris-Cl pH 7.4; 200 mM NaCl), and 
centrifugated at 5.000 g at 4 °C for 10 min. The cell 
pellet was resuspended in 7-10 ml of 0.02 M phos-
phate buffer pH 7 and lysed in the sonicator at 60 Hz 
for 10 min. The supernatant containing of KatG was 
centrifuged at 10.000 g in 4 °C for 20 minutes and 
stored at -20 °C [6-8]. 
protein purification. Purification of KatG 
protein was carried out by affinity chromatogra-
phy method using HisTrap HP column containing 
Ni-Sepharose matrix. Protein sample first setted to 
pH 7.4 in sodium phosphate buffer containing 25-
50 mM NaCl and 10 mM imidazol. Before the pro-
tein sample was filled in HisTrap column, first the 
column was washed and balaced respectively with 
milli-Q water and  binding buffer (50 mM NaH2PO4 
pH 7.4, 25 mM NaCl, 10 mM imidazole) as much as 
5 times of the column volume. After protein sample 
was flowed in column, the liquid that came out of the 
column was accommodated. The protein was eluted 
with binding buffer containing of 50-200 mM imi-
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dazole [6, 9]. Each fraction was accommodated per 
1 ml, then the presence of KatG protein in the frac-
tion was detected by sodium dodecyl sulfate - poly-
acrylamide gel electrophoresis. (SDS PAGE) [6, 8].
sDs-page. The KatG protein was analyzed 
by SDS PAGE using 12% (w/v) and 4% (w/v) acryla-
mide for separating and stacking gel respectively 
based on Sambrook method [12].
protein concentration assay. A total of 5 µl 
protein sample coupled with 795 µl of distilled wa-
ter, then added with Bradford reagent until a final 
volume of 1 ml. After the mixture was incubated for 
5 min at room temperature, the absorbance of the 
mixture was read by UV-Vis spectrophotome ter at 
595 nm. The BSA was used as standar in the assay 
[12].
production of antibody. activation as a vac-
cine. The KatG protein as antigen protein was added 
with complete Freund's adjuvant (CFA) (ratio 1 : 1), 
then mixed in vortex for 30 mins. The active antigen 
protein was further used as a vaccine for  the experi-
mental animal [12, 14].
mice immunization and serum isolation. 
Immunization was done three times to female mice 
Balb/C, aged 8-10 weeks with KatG antigen. The 
work was clustered  in 4 treatments with 6 repeti-
tions. First immunization, the mice were injected 
intraperitoneally by mixture of KatG in varing con-
centration 5, 15, and 45 µg/ml with CFA (ratio 1 : 1) 
in total volume of 100 µl. For control, it was used 6 
mice with a strain, sex, and the same age, but injec-
ted with phosphate buffer saline (PBS) without an-
tigen. The second immunization was done 14 days 
after the first immunization. The mice were injected 
by a mixture of KatG with incomplete Freud’s adju-
vant (ICFA) in the ratio 1 : 1. The third immuni-
zation was completed after 28 days, and the mice 
were only injected by KatG antigen in PBS without 
adjuvant [12-14].
Five days after the last immunization, the blood 
of the mice was drawn from their heart, then col-
lected into tubes and stand at room temperature for 
2 h to coagulate the red blood cells. Furthermore, 
the blood was centrifuged at 3000 rpm at 4 °C for 
10 min. Serum was collected to measure the anti-
body titers and serotyping assay [12, 15].
Determination of antibody content. The 
measurements of antibody levels  was detected with 
Protein Detector™ Peroxidase ELISA Kits, KPL 
Inc. One hundred µl of recombinant proteins was 
filled in the microplate with 96 wells, incubated at 
4 °C for 24 hours to coat the plate well, then added 
with 200 µl 10% (w/v) of BSA as blocking reagent 
and re-incubated for 15 min at room temperature. 
To each of the wells was added 100 µL of primary 
antibody in PBS derived from serum, then incu-
bated at room temperature for 1 hour and followed 
by washing the each well with 300 µl wash solu-
tion. To each of the wells was added with 100 µl of 
HRP - anti-mouse IgG conjugate and incubated for 
1 h at room temperature, then washed with 300 µl 
wash solution and repeated three times. Additiona-
lly, each of the wells was added 100 µl substrate 
of 3,3′5,5′-tetramethylben zidine (TMB). Finally, it 
was added 100 µl stop solution to every well. Op-
tical density of antibody was measured at 450 nm 
[12, 13, 15].
antibody isotyping assay. The 100 µl of se-
rum samples  and positive control working solution 
filled respectively to the test samples wells, then it 
sealed by a cover and incubated at 37 °C for 90 min. 
Subsequently, the cover was removed and the plate 
content discharged. The 100 µl of biotin – Anti – 
mouse IgG1, IgG2a, IgG2b, IgG2c, IgG3 and IgM 
antibodies working solution was added to the test 
samples wells respectively. The 6 Biotin – antibodies 
were also reacted to the positive control. The plate 
was sealed with a cover and incubated at 37 °C for 
60 min. Subsequently, the cover was removed and 
plate washed 3 times with wash buffer. The 100 µl 
of HRP – Streptavidin Conjugate (SABC) working 
solution was added to each well, the the plate was 
cove red and incubated at 37 °C for 60 min. The 
cover was removed, and plate washed 5 times with 
wash buffer.  The 90 µl of TMB substrate was added 
to each well and incubated at 37 °C in dark within 
15 min. The 50 µl of stop solution was added to each 
well and mix thoroughly. The absorbance of yellow 
product was recorded at a wavelength (λ) of 450 nm 
[12, 15, 24].
results and Discussion
The best and potential antigens for subunit 
vaccine against TB are continuously sought after se-
quencing of the M. tuberculosis genome. However 
the antigen candidate should be released by intra-
cellular mycobacteria which has many promiscuous 
epitopes to be presented to MHC class I and MHC 
class II, and can emerge a strong Ag-specific type 1 
immune response [16-20]. This paper showed that 
KatG of M. tuberculosis has a potential antigen for 
vaccine candidate, because it can induce a high anti-
body response in the experimental animal. 
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the antigen of Katg l19 protein. The KatG 
protein used for antigen was produced by expres-
sion of katg gene (2.2 kb) of M. tuberculosis clini-
cal isolate L19 in e. coli BL21(DE3) using pCold II-
DNA vector. The KatG protein 80 kDa was found 
in extract of e. coli BL21(DE3) recombinant after 
it analyzed by SDS PAGE. The KatG protein was 
absent in extract from non recombinant of e. coli 
BL21(DE3) (Fig. 1, lane 1 and 2). The KatG L19 
protein in extract then was purified by using affinity 
chromatography based on Immobilized Metal Affini-
ty Chromatography (IMAC). The pure of KatG L19 
protein resulted a band 80 kDa in SDS-PAGE after 
the protein extract eluted with sodium phosphate 
buffer containing 150 mM imidazole (Fig. 1, lane 3). 
The pure of KatG L19 was further used as antigen 
for immunization in mice.  
Fig. 1. Profile of KatG L19 protein in SDS–PAGE 
electropherogram before and after purified by af-
finity chromatoghraphy method. Lane M, protein 
marker; lane 1, extract of protein from e. coli had no 
a katg recombinant; lane 2, extract of protein from 
e. coli containing a katg recombinant; lane 3, pure 
katg protein (80 kda) after eluted with 150 mM imi-
dazole from column
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antibody response of mice against to Katg 
l19. Immunization of mice with pure KatG L19 pro-
tein was performed in various doses 5, 15 and 45 µg/
ml. The antibody product of each threatment was re-
corded by ELISA method. The KatG can elicite a 
high antibody response in mice after the experimen-
tal animal injected by the protein in various doses. 
The highest antibody in our research was reached 
when the mice vaccinated by KatG L19 in the dose 
of 45 µg/ml (Table and Fig. 2). Antibody response 
against to KatG at various doses of 0, 5, 15 and 
45 µg/ml showed a  significant differences among all 
treatments. The Anova and Duncan tests also con-
firmed the differences with score of P < 0.05, except 
for antibody product from the KatG antigen with 
doses 0 and 5 µg/ml (Table).
The optimal of antigen doses is a crutial to be 
investigated in the vaccination process, since the 
antigen dose significantly affects T cell functional 
avidi ty, differentiation status, and their subsequent 
protection against TB. Optimal protective capacity 
of T cells against M. tuberculosis infection relies on 
the optical density (od450nm) of antibody response in mice after injected by katg L19 in various doses
The test of ANOVA and Duncan presented a significance difference when the p score achieved at least 5%. No significant 
difference of antibody product was found in antigen dosages of 0 and 5 µg/ml, whereas the others had significant value
Treatment
Repetition everage 
(χ)
SD
1 2 3 4 5 6
0 µg/ml 0.266 0.112 0.172 0.160 0.141 0.107 0.159 0.057a
5 µg/ml 0.446 0.270 0.322 0.252 0.340 0.430 0.343 0.080a
15 µg/ml 0.633 0.335 0.477 0.419 0.896 0.521 0.546 0.197b
45 µg/ml 1.824 1.192 1.373 1.170 1.557 1.424 1.423 0.244c
Fig. 2. Grafic of antibody levels produced by mice 
after injected with katg L19 in various dosages. the 
KatG with dosage of 45 µg/ml gave a high response 
for antibody production in mice
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Fig. 3. histograme of antibody types which produced by mice with present and absent of katg L19 protein. 
The KatG L19 protein induced significantly the production of IgG1, IgG2a, IgG2b, IgG2c, IgG3 in mice
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the ability of T cells to home into the lung paren-
chyma to make close contact with granuloma resi-
dent Mtb-infected host cells.  The quality of T cells 
becomes very important in the protection of tuber-
culosis vaccines which provided by a significant role 
of antigen doses in vaccine-mediated protection [11]. 
Immunogenicity profile of KatG L19. The 
imunogenicity analysis of KatG requires information 
of the present specific immunoglobulin of IgG in se-
rum which does a main role against to pathogens. In 
human, the immunoglobulin is the most abundant 
antibody isotype which found in the circulation and 
provide the majority of antibody-based immunity 
against invading pathogens [21-23].
The KatG which injected in mice stimulated 
the expression of six antibody types, i.e IgG1, IgG2a, 
IgG2b, IgG2c, IgG3 and IgGM. Of the antibodies, 
the IgG2c and IgG2a isotypes emerged higher that 
other, whereas  IgM  was expressed in the lowest 
content (Fig. 3). The first and second highest OD 
of immunoglobulin were found on the type IgG2c 
and IgG2a isotypes in all treatment groups for KatG 
doses of 5, 15 or 45 µg/ml. The data suggest that 
KatG elicits a high immunogenicity effect through 
the formation of IgG which is subsequently used to 
realize an immune response, so it is a possible to be 
deveoped as vaccine candidate in future. 
The IgM antibody was produced quite a bit in 
mice after it immunized by KatG for 35 days. The 
IgM is classified as the first-line antibody for de-
fense against infection from antigen proteins. High 
production of IgM can occur when the first week 
of infection, then decrease in the remaining weeks 
[17, 23]. Because of the blood isolation in this study 
was performed on day 35, so the obtained IgM level 
was low. The IgG2c and IgG2a subclasses were the 
highest immunoglobulin that appears in blood serum 
of mice, this might be due to their abilities to re-
spond antigen proteins. Immunohistochemistry as-
say is developed in future to detect the lymphocytes 
level of CD4 and CD8 to provide well on the rela-
tionship of the antibody response with the number 
of lymphocyte cells. 
conclusion. The KatG L19 from clinical iso-
late of M. tuberculosis stimulate significantly im-
mune response in mice to produce antibody. The 
protein induces the formation of immunoglobulin 
IgG1, IgG2a, IgG2b, IgG2c, IgG3, and IgM, where 
the IgG2c isotype produced dominantly. The high 
immunogenic exposed by KatG L19 encourages its 
development as a protein candidate for TB vaccine, 
so it needs to develope a clinical testing for the pro-
tein in future.  
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Туберкульоз залишається одним з пошире-
них захворювань, хоча багато людей пройшли 
вакцинацію БЦЖ. Неефективність вакцини 
БЦЖ є однією з причин, які ускладнюють про-
філактику поширення туберкульозу. Метою до-
слідження було визначення імуногенності про-
теїну KatG в клінічному ізоляті L19 штаму M. 
tuberculosis у мишей. KatG в якості антигену 
отримували експресією гена katg клінічного ізо-
ляту L19 M. tuberculosis в escherichia coli BL21 
з використанням вектора pColdII-DNA. KatG 
після очищення афінною хроматографією вико-
ристовували для вакцинації мишей. Експресією 
katG в e. coli BL21 одержували протеїн KatG із 
молекулярної масою 80 кДа за електрофорезу на 
PAGE-SDS. Очищений протеїн KatG значно сти-
мулював імунну відповідь мишей, спричиню-
ючи продукування антитіл IgG1, IgG2a, IgG2b, 
IgG2c, IgG3 і IgM. Найвищий рівень антитіл 
спостерігали у разі вакцинації мишей KatG L19 
в дозі 45 мкг/мл. Серед антитіл IgG2c-ізотип 
переважно продукувався в сироватці крові. По-
казано, що протеїн KatG виявляє високу імуно-
генність у мишей, і може бути запропонований 
як потенціальна вакцина проти туберкульозу. 
Необхідно в подальшому провести клінічні до-
слідження для оцінки безпеки його застосуван-
ня як терапевтичного протеїну.
К л ю ч о в і  с л о в а: KatG, імуногенність, 
M. tuberculosis, вакцина, клінічний ізолят.
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Туберкулез остается одним из широко рас-
пространенных заболеваний, хотя большинство 
людей вакцинированы БЦЖ. Неэффективность 
вакцины БЦЖ является одной из причин, кото-
рые затрудняют профилактику распространения 
туберкулеза. Целью исследования было опреде-
ление иммуногенности протеина KatG в кли-
ническом изоляте L19 штамма M. tuberculosis у 
мышей. KatG в качестве антигена получали экс-
прессией гена katg клинического изолята L19 M. 
tuberculosis в escherichia coli BL21 с использова-
нием вектора pColdII-DNA. KatG после очистки 
аффинной хроматографией использовали для 
вакцинации мышей. Экспрессией katG в e. coli 
BL21 получали протеин KatG с молекулярной 
массой 80 кДа при электрофорезе на PAGE-SDS. 
Очищенный протеин KatG значительно стиму-
лировал иммунный ответ мышей, вызывая про-
дуцирование антител IgG1, IgG2a, IgG2b, IgG2c, 
IgG3 и IgM. Самый высокий уровень антител 
наблюдали при вакцинации мышей KatG L19 
в дозе 45 мкг/мл. Среди антител IgG2c-изотип 
преимущественно продуцировался в сыворотке 
крови. Показано, что протеин KatG проявляет 
высокую иммуногенность у мышей, и может 
быть предложен в качестве потенциальной вак-
цины против туберкулеза. Необходимо в даль-
нейшем провести клинические исследования 
для оценки безопасности его применения в ка-
честве терапевтического протеина.
К л ю ч е в ы е  с л о в а: KatG, иммуноген-
ность, M. tuberculosis, вакцина, клинический изолят.
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